Literature DB >> 21811095

Finally, how histone deacetylase inhibitors disrupt mitosis!

Brian Gabrielli1, KeeMing Chia, Robyn Warrener.   

Abstract

The disruption of normal mitosis by histone deacetylase inhibitors is a significant contributor to the anticancer effects of these drugs. However, the mechanism by which these drugs affect mitosis is poorly understood. A number of recent papers have now thrown considerable light onto how these drugs elicit this very distinctive cell cycle disruption.

Mesh：

Substances：

Year:  2011        PMID： 21811095     DOI： 10.4161/cc.10.16.16953

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


  5 in total

1.  In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Authors:  Girija Dasmahapatra; Hiral Patel; Johnathan Friedberg; Steven N Quayle; Simon S Jones; Steven Grant
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

2.  Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.

Authors:  Aaron P Havas; Kameron B Rodrigues; Anvi Bhakta; Joseph A Demirjian; Seongmin Hahn; Jack Tran; Margarethakay Scavello; Ana A Tula-Sanchez; Yi Zeng; Monika Schmelz; Catharine L Smith
Journal:  Cancer Biol Ther       Date:  2016-10-28       Impact factor: 4.742

3.  Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.

Authors:  Marion Wobser; Alexandra Weber; Amelie Glunz; Saskia Tauch; Kristina Seitz; Tobias Butelmann; Sonja Hesbacher; Matthias Goebeler; René Bartz; Hella Kohlhof; David Schrama; Roland Houben
Journal:  J Hematol Oncol       Date:  2019-03-18       Impact factor: 17.388

4.  The multi zinc-finger protein Trps1 acts as a regulator of histone deacetylation during mitosis.

Authors:  Manuela Wuelling; Markus Pasdziernik; Carina N Moll; Andrea M Thiesen; Sabine Schneider; Christian Johannes; Andrea Vortkamp
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

5.  A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.

Authors:  Ana A Tula-Sanchez; Aaron P Havas; Peter J Alonge; Mary E Klein; Samantha R Doctor; William Pinkston; Betty J Glinsmann-Gibson; Lisa M Rimsza; Catharine L Smith
Journal:  Cancer Biol Ther       Date:  2013-08-02       Impact factor: 4.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.